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Insulin dependent diabetes mellitus (IDDM) is an autoimmune disease associated with the presence of
different types of autoantibodies. The presence of these antibodies and the corresponding antigens in
the circulation leads to the formation of circulating immune complexes (CIC). CIC are known to persist
in the blood for long periods of time. Such CIC following deposition in the small blood vessels have the
potential to lead to microangiopathy with debilitating clinical consequences. The aim of our pilot study
was to investigate whether a correlation exists between CIC and the development of microvascular
complications in diabetic children. Isolation of a new glycoprotein complement inhibition factor (CIF)
from the parasitic plant Cuscuta europea seed, which appears to bind speciﬁcally to complement
component C3 has provided an unique tool for the measurement of immune complexes by means of
ELISA-type techniques (CIF-ELISA). We studied the levels of CIC (IgG, IgM and IgA) in 58 diabetic
children (mean age 12:28 ^ 4:04 years, diabetes duration 5:3 ^ 3:7 years), 29 of them had vascular
complications (group 1) and the other 29 were without vascular complications (group 2). As controls,
we studied sera samples from 21 healthy children (mean age 13.54 ^ 4.03 years). Sera from the
diabetic patients showed statistically signiﬁcant higher levels of CIC IgG ðp ¼ 0:03Þ than sera from the
control group. In sera from group 1 values of CIC IgG showed statistically signiﬁcant higher levels than
controls (0:720 ^ 0:31 vs. 0:46 ^ 0:045; p ¼ 0:011) Sera from 59% of the patients were positive for
CIC IgG, 36% for CIC IgM and 9% for CIC IgA. Among 26 patients with microalbuminuria, sera from
17/26 (65%) were positive for CIC IgG, 8/26 (31%) for CIC IgM and 2/26 (8%) for CIC IgA. CIC IgG
correlated with HbA1c (r ¼ 0:51; p ¼ 0:005) and microalbuminuria (r ¼ 0:42; p ¼ 0:033). CIC IgA
correlated with age (r ¼ 0:44; p ¼ 0:03). CIC IgM correlated with the duration of diabetes (r ¼ 0:63;
p ¼ 0:02). These ﬁndings suggest that elevated levels of CIC IgG are associated with the development
of early diabetic nephropathy.
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INTRODUCTION
Immune complexes are a heterogeneous high molecular
weight aggregates composed of antigens and immuno-
globulins elicited in response to antigens, and in most
cases, include complement component C3 (Stanilova and
Slavov, 2001). When immune complexes are produced
faster than they can be cleared from the circulation,
immune complex disease may occur. Examples of such
disorders include drug sensitivity, rheumatoid arthritis
and systemic lupus erythematosus (SLE). The presence
of detectable immune complexes in the blood is
considered important for the diagnosis of autoimmune
diseases in general.
Type 1 (insulin-dependent) diabetes mellitus results
from the progressive autoimmune destruction of pancrea-
tic beta cells (Bottazzo, 1993). On the other hand,
an important factor for the development of diabetic
vascular complications is the alteration in the structure of
the vascular proteins. Peptides derived from such
processes have been found in the circulation (Nicoloff
et al., 2000a, 2001) and they are reasoned to be a stimulus
for increased production of autoantibodies. A variety of
autoantibodies have been documented in diabetes and
include insulin autoantibodies, GAD-autoantibodies,
tyrosine phosphatase IA2-autoantibodies, islet cell-auto-
antibodies, (Verge et al., 1998) elastin autoantibodies
(Nicoloff et al., 2000b) and collagen type IV auto-
antibodies (Nicoloff et al., 2002). These autoantibodies
bind to their cognate antigen and thus form circulating
immune complexes (CIC). CIC could persist in the blood
for a long time. Such CIC have pathogenic potential since
following deposition on small blood vessels they give rise
to microangiopathy.
Recently, the identiﬁcation of a new glycoprotein
termed the complement inhibition factor (CIF) isolated
from the parasitic plant Cuscuta europea seed, which
appears to bind speciﬁcally to complement component
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Clinical & Developmental Immunology, March 2004, Vol. 11 (1), pp. 61–66C3 (Zhelev et al., 1994) has provided a novel method for
the detection and quantitation of immune complexes
detection using standard ELISA based techniques
(CIF-ELISA) (Stanilova and Slavov, 2001). The aim of
our pilot study is to investigate utilizing this newly deﬁned
CIF-ELISA the levels of CIC (IgG, IgM and IgA).
T oa c h i e v et h i so b j e c t i v ew es t u d i e dat o t a lo f
58 diabetic children. The data obtained on the samples
from these patients were compared with a control group of
21 otherwise healthy age matched children.
MATERIALS AND METHODS
Subjects
The baseline study population consisted of a total of 58
patients (25 boys and 33 girls) with Type 1 diabetes
mellitus (mean age 12:28 ^ 4:04 years) diagnosed
according to the WHO deﬁnition and for purposes of
control a group of 21 healthy children of similar age
(13:54 ^ 4:03) and sex with no family history of
diabetes, atherosclerosis, and/or nephropathy. The patients
are all diabetic children residing in the vicinity of the
Pleven University Hospital. All patients were treated
with a standard dose of human insulin obtained
from Novo Nordisk Industri, Copenhagen, Denmark.
None of the subjects were taking anti-hypertensive
medication prior to the appearance of persistent micro-
albuminuria. None of the patients had a diagnosis of renal
disease unrelated to diabetes.
The mean duration of diabetes was 5:3 ^ 3 years. All
subjects were being administered 2–4 subcutaneous doses
of insulin per day. Twenty-nine of the 58 diabetics
developed vascular complications. Of these 29 patients,
19 showed evidence of microalbuminuria, 3 developed
high blood pressure, 2 developed both retinopathy and
microalbuminuria, 4 developed both microalbuminuria
and high blood pressure and 1 microalbuminuria, high
blood pressure and retinopathy (see Table I).
Microalbuminuria was deﬁned as a persistent urinary
albuminexcretionrate(AER)intherangeof20–200mg/min
in urine. Levels of hemoglobin A1c (HbA1c), total serum
cholesterol, triglycerides and AER were measured as
described earlier (Nicoloff et al., 2000a). Levels of HDL
were quantitated using the quantitative enzyme method
for direct detection (test-kits HDL-C plus, Roche).
Ethical approval was obtained from the local research
ethics committee and the parents of all subjects
gave a written informed consent prior to enrolment in
the study.
Procedure
Isolation of CIF was performed according to the protocol
developed by Stanilova and Slavov (2001). CIF was
isolated from C. europea seeds (Zhelev et al., 1994).
CIF-ELISA-ﬂat bottom polystyrene microtiter plates
were coated with 20mg/ml CIF in 0.2M carbonate–
bicarbonate buffer pH 9.6 and incubated overnight at 48C.
After washing with washing buffer which consisted
of 50mM Tris-HCl pH 7.2 containing 0.05% Tween 20
ð2 £ 5minÞ; the plates were blocked for 20min with the
same buffer. One hundred microlitres of 1:50 dilution of
each serum to be tested in sample buffer (0.1M PBS,
containing 1% BSA 0.2% Tween 20, 1mM CaCl2 and
MgCl2) was added to duplicate wells of the microtiter
plate and incubated for 60min at 378C. The microtiter
wells were washed twice with washing buffer and then
100ml of a 1:800 dilution of a peroxidase conjugated
sheep anti-human IgG, IgM and IgA in washing buffer
were added to appropriate wells. The microtiter plate was
incubated for 60min at 378C. The reaction was stopped by
the addition of 50ml8NH 2SO4. The O.D. 492 reading of
the wells was then determined using a Microelisa Plate
Reader 210 (Organon Teknika, Belgium).
Statistical Analyses
All values are expressed as mean ^ SD. Statistical
analyses were performed using the computer programs
Excel and Statgraphics plus for Windows. The Student’s
t-test and ANOVA were used to assess differences
between study groups. For select data sets correlation
analysis was performed and data considered signiﬁcant
with a p value of less than 0.05.
TABLE I CIC in serum of children with Type 1 diabetes mellitus with or without vascular complications (VC)
Group
CIC Positive for CIC
Sample size Positive Negative IgG IgM IgA
Diabetics 58 44 14 34/58 23/58 5/58
Without VC 29 21 8 14/29 14/29 3/29
M 19 16 3 14/19 8/19 1/19
M þ HBP 4 2 2 2/4 0/4 0/4
M þ R 2 1 1 0/2 0/2 1/2
M þ R þ HBP 1 1 0 1/1 0/1 0/1
HBP 3 3 0 3/3 1/3 0/3
The table shows the frequency of samples positive for CIC (IgG, IgM and IgA) in each group.
VC, vascular complications; M, microalbuminuria; R, retinopathy; HBP, high blood pressure.
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The clinical data of the tested patients are presented in
Table II. The patients were divided into two groups
based on the presence (group 1) or absence (group 2) of
vascular complications. The mean ^ 2 S.D. value was
calculated on data obtained on sera samples from the
control study group in efforts to deﬁne the normal range
of CIC (IgG, IgM, IgA) and a cut-off value for
classifying a sample as being positive. The results of
this analysis are presented in Table III. As seen,
diabetics showed statistically signiﬁcant higher levels of
CIC IgG than controls (0:672 ^ 0:300 vs. 0:46 ^ 0:045;
p ¼ 0:03). While the CIC IgG values obtained on
samples from Group 1 were not signiﬁcantly different
from the group 2 (Table II), CIC IgG values obtained
from groups 1 and 2 differed in terms of their
signiﬁcance to control values. Thus, while values of
CIC IgG were statistically signiﬁcant as compared with
controls (0:720 ^ 0:31 vs. 0:46 ^ 0:045; p ¼ 0:011),
values obtained on samples from group 2 did not show
statistically signiﬁcant difference as compared with
controls (0:62 ^ 0:29 vs. 0:46 ^ 0:045; p ¼ 0:28).
Thirty-four (59%) of the patients were positive for
CIC IgG and 21 (36%) for CIC IgM. Five (9%) of the
patients were positive for CIC IgA (Table I). From the
34 positive samples for CIC IgG 23 (68%) belonged to
group1 and 14 (41%) to group 2. From the 23 positive
samples for CIC IgM, 9 (39%) belonged to group 1 and
14 (61%) to group 2. Seventeen patients with
microalbuminuria were positive for CIC IgG, 8 for
CIC IgM and 2 for IgA. One of three diabetics with
retinopathy had raised level of CIC IgG. Eight patients
had high blood pressure, six of them were positive for
CIC IgG and 1 for CIC IgM. CIC IgG of all patients
was associated with diastolic blood pressure (r ¼ 0:29;
p ¼ 0:032). Values for CIC IgG in the patients with
vascular complications correlated with values of HbA1c
(r ¼ 0:51; p ¼ 0:005) and microalbuminuria (r ¼ 0:42;
p ¼ 0:033). While the values for CIC IgA correlated
with age (r ¼ 0:44; p ¼ 0:03), the values of CIC IgM
correlated with the duration of diabetes (r ¼ 0:63;
p ¼ 0:02). The p values for differences between
groups 1 and 2 in terms of age ðp ¼ 0:0007Þ; mean
diabetes duration ðp ¼ 0:0004Þ; diastolic blood pressure
ðp ¼ 0:01Þ; insulin dose ðp ¼ 0:001Þ and microalbumi-
nuria ðp ¼ 0:0001Þ are shown in Table II.
DISCUSSION
In the present study, children with Type 1 diabetes mellitus
were studied for levels of isotype speciﬁc immune
complexes utilizing a newly developed ELISA assay.
We chose children as a subject for the study because in
adults CIC occur due to a variety of different pathological
reasons. Using diabetic children it was easier to exclude
the other factors (except diabetes) which lead to the
formation of CIC. Individuals with juvenile onset Type 1
diabetes mellitus are at a high risk for the development
of diabetic microangiopathy and vascular disease
(Linderkamp et al., 1999).
Similar studies on the quantitation of CIC levels have
been conducted on a variety of autoimmune disease
including systemic sclerosis (Stanilova and Slavov, 2003),
SLE and rheumatoid arthritis (O ¨lmez et al., 1991;
Stanilova and Slavov, 2001). Type 1 diabetes mellitus is
also an autoimmune disease in which different types of
autoantibodies have been identiﬁed such as those against
beta cells (insulin-autoantibodies, islet cell-autoanti-
bodies, GAD autoantibodies (Verge et al., 1998)) and
antibodies against vascular wall proteins such as elastin
(Nicoloff et al., 2000b) and collagen (Nicoloff et al.,
2002). Our aim in the studies reported herein was to test
the relationship between CIC and vascular complications
in diabetic children.
TABLE II Clinical characteristics of diabetic patients with or without vascular complications
CLINICAL DATA Group 1 (with vascular complications) n ¼ 29 Group 2 (without vascular complications) n ¼ 29 P
Age (years) 14.03 ^ 3.6 10.5 ^ 3.9 0.0007
Mean duration (years) 6.9 ^ 3.2 3.6 ^ 3.43 0.0004
Mean glycated hemoglobin(%) 10.35 ^ 1.6 10.4 ^ 1.3 NS
Systolic blood pressure (mmHg) 110.3 ^ 14.3 104.8 ^ 11.2 NS
Diastolic blood pressure (mmHg) 75.5 ^ 11.1 68.8 ^ 7.9 0.01
Triglycerides (mmol/l) 1.37 ^ 0.58 1.14 ^ 0.57 NS
Total cholesterol (mmol/l) 4.71 ^ 0.84 4.82 ^ 0.76 NS
Dose (U/kg/24h) 1.11 ^ 0.29 0.85 ^ 0.28 0.0011
Microalbuminuria (mg/min) 37.76 ^ 16.9 10.14 ^ 3.18 0.0001
High density lipoprotein (mmol/l) 1.33 ^ 0.34 1.16 ^ 0.19 NS
CIC IgG (E
492) 0.72 ^ 0.31 0.62 ^ 0.29 NS
CIC IgM (E
492) 0.14 ^ 0.05 0.15 ^ 0.04 NS
CIC IgA (E
492) 0.16 ^ 0.04 0.16 ^ 0.04 NS
TABLE III Study of the levels of circulating immune complexes (CIC
IgG, CIC IgM, CIC IgA) in diabetics and control sera using CIF-ELISA
IgG IgM IgA
XS DXS DXS D
Diabetics 0.672 0.300 0.143 0.045 0.160 0.042
Controls 0.46 0.045 0.124 0.015 0.137 0.035
X ^ 2S.D. 0.55 0.37 0.154 0.094 0.207 0.067
IMMUNE COMPLEXES AMONG DIABETES 63Our laboratory has previously reported results of ELISA
based speciﬁc titers of elastin-speciﬁc CIC (Baydanoff
et al., 1988) using sequential precipitation of CIC by
increasing concentrations of polyethylene glycol (PEG).
This method is not only time consuming but also labor
intensive as compared to the CIF-ELISA described herein.
As noted in the present study, the values for CIC in
samples from adult diabetics with vascular complications
were markedly higher than healthy controls.
This relationship between vascular complications and
levels of CIC in the sera of diabetic patients has also been
reported by others (Adreani et al., 1982; Di Mario et al.,
1983; Baranao et al., 1985; Baydanoff et al., 1988; Turk
etal.,2001).Thus,whilesomestudiesreportedacorrelation
betweenvascularcomplicationsandthedetectionofelastin-
speciﬁc CIC (Baydanoff et al., 1988), others have reported
AGE-containing CIC (Turk et al., 2001), insulin-CIC
(Triolo et al., 1984), and/or total CIC (Adreani et al.,1 9 8 2 ;
Di Mario et al.,1 9 8 3 ;B a r a n a oet al., 1985). In the present
studyweinvestigatedtotalCIC.Andreanietal.(1982)used
a solid phase C1q (C1q SP) binding test and conglutinin
radioimmune assay (RIA) for the detection of CIC.
The results obtained using the C1qSP method showed both
anincreaseintheprevalenceandquantityofCICindiabetics
with severe microangiopathy regardless of the duration of
thediseaseandtypeofdiabetes.WhenCICweredetectedby
RIA, they were found to be at a higher prevalence in
diabetics than in normal controls but no correlation was
noted with the occurrence of microangiopathy. CIC,
detected by RIA, were higher in long standing Type1
diabetics. These differences in the results can be explained
by the view that CIC present in diabetics seems are
heterogeneous in nature with a proportion of them being
relatedtotheoccurrenceofmicroangiopathy(Adreanietal.,
1982). Thus, as reported herein, diabetics with microangio-
pathy showed increased levels of CIC as compared to
controls. These results are similar to the results obtained by
RIA. In addition, we also noted a correlation between
microalbuminuria (a microvascular complication) and
levels of CIC IgG.
CIC differ in size which is determined by the ratio of
antigen–antibody, the valence and nature of antigen and
the afﬁnity and class of antibodies. Based on size the large
CIC appear as insoluble proteins which are rapidly cleared
from the circulation facilitated by mononuclear phago-
cytes and therefore, do not accumulate along vessel walls.
Presence of a large excess of the auto-antigen leads to the
formation of small CIC. The smaller CIC are thus more
harmful since they are deposited in the small blood vessels
of the microcirculation. Such deposition of CIC results in
microangiopathy, and in our case microalbuminuria.
There is evidence that proteins, including immunoglobu-
lins, accumulate in the matrix lining of the walls of small
blood vessels in diabetic subjects (Wilson et al., 1991).
This is supported by the fact that the amount of IgG cross-
linked to the glomerular basement membrane is ﬁve times
higherindiabeticthaninnondiabeticrats(Brownleeetal.,
1983). IgG binds preferentially to the basement
membranes, which leads to accelerated non enzymatic
glycation of proteins and advanced glycation end products
(AGE, Brownlee et al., 1983).
A previous study reported levels of CIC in 57 diabetic
patients (Baranao et al., 1985). In these studies the levels
of CIC were quantitated by the binding of CIC to human
red blood cells through the C3b complement fraction,
a radioimmunoassay using
125I labeled anti-human IgG
(HRBC RIA test) and CIC precipitation using 3.5% PEG
(PEG test). Patients were divided in two groups according
to the type of diabetes. Their results showed that CIC
levels were signiﬁcantly higher in both groups of patients
when compared to normal controls. Type 1 diabetes
patients with microangiopathy present higher CIC levels
as measured by HRBC RIA test than Type 1 patients
without microvascular complications, while no difference
was found within the Type 2 group.
There have also been reports for antibodies against C1q
complement component in the sera of patients with
different diseases. These antibodies are one of the reasons
for false positive results as detected by using the C1q-
ELISA (Haseley et al., 1997; Walport et al., 1998).
Therefore it is possible that a part of the C1q-ELISA
positive results was due to such antibodies and not to CIC.
In contrast to these assays, the assay described herein
utilized a protein isolated from a parasitic plant which
minimizes the potential of cross-reactivity (Stanilova and
Slavov, 2001). In addition, ELISA is a highly sensitive
and speciﬁc immunological assay. It is easier to
accomplish and cheaper than radioimmunological tests
which not only require specialized equipment for work
involving radioactive substances but is considered
ecologically unsafe.
An additional two fundamental risk factors associated
with microalbuminuria need address. This includes
elevated blood pressure and elevated serum glucose
concentration. The signiﬁcance of lipid proﬁle (elevated
concentration of triglycerides and total cholesterol) also
needs to be taken into account (Microalbuminuria
Collaborative Study Group, United Kingdom, 1993;
Poulsen et al., 1994; Mortensen and Poulgaard, 1997).
An increase in the levels of plasma triglycerides which are
a rich lipoprotein species that are potentially atherogenic
has expanded the picture of diabetic dyslipidaemia
(Taskinen, 2003). It is the most common abnormality
found in poorly controlled diabetes. In CIC positive
patients with microvascular complications, the binding of
the triglycerides to the arterial wall proteins may convert
these proteins into an immunogenic form. In the
present study, tryglycerides were over the normal limit
in the group of patients with vascular complications
supporting this view.
The accelerated non-enzymatic glycation of proteins
may also potentially be a reason for the formation of new
epitopes. Advanced glycation of protein may thus increase
immunogenicity. The fact that AGEs has shown to possess
antigenic properties has led to the hypothesis that
the physico-biochemical structure of AGE may change
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response (Turk et al., 2001). It is possible that some of CIC
detected in the studies reported herein contain AGE and
anti AGE complexes. Turk et al. (2001) reported that the
content of AGE in soluble immune complexes was
signiﬁcantly higher in the sera of diabetic patients than in
control subjects and correlated inversely with the level of
AGE speciﬁc free antibodies. Interactions of AGE
autoantibodies with AGE as a continuously produced
antigen result in the formation of AGE-immune
complexes that may play a role in the atherogenic process
(Turk et al., 2001). The development of microvascular
disease is associated with high percentage of glycated
hemoglobin (HbA1c). In this study CIC IgG of diabetic
group 1 correlated with HbA1c. HbA1c is a classical
example of AGE. These results support the hypothesis for
accelerated non-enzymatic glycation.
Our results showed that the highest levels of CIC
were of the IgG isotype followed by IgM and then
IgA. The formation of IgM antibodies precedes the
development of IgG antibodies against a given immuno-
gen by a process termed Ig class switching. The elevation
of CIC of the IgM and IgG types is therefore the ﬁrst
indicator of pathological turnover and the development
of microvascular complications in diabetic children.
The highest percent of patients with elevated levels of
CIC IgM was found in group 2 (61%). It is of interest to
study whether these children will go on to develop
microvascular complications, and as such CIC IgM may
be used as a predictor of diabetic vascular damage. We did
not ﬁnd signiﬁcant elevation of CIC IgA in patients.
The low frequency of patients with CIC IgA (9%) may be
explained by the fact that IgA appears during the later
stages of the disease. It is important to note that the highest
levels of CIC IgG was seen in one patient who had
elevated blood pressure and the other had microalbumi-
nuria. Triolo et al. (1984) examined the sera of middle age
Type 1 and Type 2 diabetics for the presence of IgA- and
insulin-containing CIC using a solid-phase anti-C3
enzyme immunoassay. CIC IgM and CIC IgG were also
investigated. The patients groups were divided according
to the treatment. The authors found CIC IgA to be
associated with the presence of microangiopathy,
suggesting that they may play a role in the pathogenesis
of the late diabetic complications (Triolo et al., 1984).
In the present study we also investigated CIC IgM, CIC
IgG and CIC IgA, but the results showed an association of
CIC IgG with microangiopathy. This contradiction
between our results could be due to the different ages of
the two study populations, the type of diabetes, the
methodology utilized for the assays utilized.
Most of our patients with vascular complications had
microalbuminuria. Only three patients were reported
to have high blood pressure without microalbuminuria.
The retinopathy or high blood pressure was developed
after the onset of microalbuminuria.
The prevalence of microalbuminuria in Type1 diabetic
patients is a sensitive predictor of future development of
diabetic nephropathy. Diabetic nephropathy is the leading
cause of end-stage renal disease. Because early diagnosis
and treatment may prevent the complication, new tools for
early detection are also needed. Microalbuminuria is
a recognized risk factor for increased mortality and
renal failure in Type 1 diabetes (Kate and Walker, 2003).
Risk factors for the development of nephropathy include
positive family history, male sex, poor glycemic control,
hypertension, smoking and the presence of retinopathy
and coronary artery disease. The pathogenesis of
glomerulonephritis involves three phases of injury.
The ﬁrst is usually an antigen-antibody reaction that
secondarily activates one or more chemical mediators and
stimulates resident cells to proliferate and/or transform
metabolically. At this point the glomerulus is not
irreversibly damaged and can heal. The third phase is
progression to chronic disease due to buildup of
glomerular basement membrane material resulting in
sclerosis and an obliteration of the surface area
responsible for ultraﬁltration.
The passage of proteins across the glomerular ﬁltration
barrier is regulated by several factors. Small proteins, such
as albumin, ﬁlter through approximately 5.5nm of
glomerular pores, while immunoglobulins, because of
their size (5.5nm), can only escape across the larger shunt
pores of alternative ﬁltration pathways (size-selectivity)
(Brenner et al., 1978). The structural basis for the
development of nephropathy is the slow expansion of the
volume of the glomerular mesangial matrix which results
in increased glomerular permeability to proteins,
decreased ﬁltration surface and hypertension. Eventually
the glomeruli becomes completely scarred. The develop-
ment of nephropathy and retinopathy are closely linked.
However, microalbuminuria was not a good marker for
diabetic retinopathy (Romero et al., 2003).
The ﬁrst manifestation of diabetic nephropathy is
microalbuminuria, which evolves into asymptomatic overt
proteinuria and later the nephrotic syndrome. Hyper-
tension often accompanies the development of proteinuria
and worsens as renal function declines. No gene for
diabetic nephropathy has so far been identiﬁed. Micro-
albuminuria not only implies the presence of renal
involvement in diabetes mellitus, but also is associated
with generalized vascular damage.
In conclusion, we suggest that elevated levels of CIC
IgG are associated with the development of early diabetic
nephropathy in children with Type 1 diabetes. Although it
has been shown that metabolic control inﬂuences the
development of microvascular disease (Klein et al., 1988),
it now appears very probable that an immunological
component is also involved in the pathogenesis of
microangiopathy. Elucidation of the mechanism whereby
immunoglobulins inﬂuence the development of micro-
vascular complication will require intensive research.
Identiﬁcation of a subset of patients who are immuno-
logically more susceptible to developing microvascular
complication may provide clinicians a tool that can be
utilized to control the development of such microvascular
IMMUNE COMPLEXES AMONG DIABETES 65complications and thus disease course. Although the
precise mechanisms by which soluble IC induce
pathological damage in diabetics have not been fully
elucidated, we have obtained sufﬁcient evidence to prove
that antigen-antibody complexes exist in diabetics which
are associated with higher frequencies of complications.
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